The Effects of Peroxisome Proliferators on Global Lipid Homeostasis and the Possible Significance of These Effects to Other Responses to These Xenobiotics
- 1 November 2002
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 973 (1) , 17-25
- https://doi.org/10.1111/j.1749-6632.2002.tb04600.x
Abstract
Peroxisome proliferators (PPs) have been shown to regulate hepatic lipid metabolism via activation of the peroxisome proliferator‐activated receptor alpha (PPAR‐α). Recent studies have revealed that PPs also exert considerable influence on certain extrahepatic tissues, including adipose tissue and lymphoid organs, in an indirect fashion. Inhibition of the proliferation of thymocytes and splenocytes and alteration of fatty acid uptake into and release from adipose tissue might be consequences of the hypolipidemic effect of PPs involving both PPARα‐dependent and ‐independent pathways. Exposure to PPs reduces the cholesterol content of circulating low‐density lipoprotein (LDL), which is the major supply of this steroid to most peripheral tissues. In addition, PPs increase serum levels of high‐density lipoprotein (HDL), which extracts cholesterol from peripheral tissues and returns it to the liver, thereby further decreasing the cholesterol content of peripheral tissues. This net flux of cholesterol from extrahepatic tissues to the liver represents a change in global lipid homeostasis. In normal healthy young mice, this hypolipidemic effect could result in loss of cholesterol and other lipids from peripheral tissues (e.g., adipose tissue, thymus, and spleen), especially from plasma membrane caveolae, which might perturb normal cellular signaling and result in tissue atrophy. On the other hand, the increased hepatic cholesterol content in the hepatocyte plasma membrane might actually enhance signaling, playing a role in the liver hypertrophy and hepatocarcinogenecally associated with long‐term PP treatment. In conclusion, it is important to consider the systemic effects of PPs, rather than to focus on the liver alone.Keywords
This publication has 51 references indexed in Scilit:
- Peroxisome-proliferator-activated receptors as physiological sensors of fatty acid metabolism: molecular regulation in peroxisomesBiochemical Society Transactions, 2001
- Cholesterol Depletion Disrupts Caveolae and Insulin Receptor Signaling for Metabolic Control via Insulin Receptor Substrate-1, but Not for Mitogen-activated Protein Kinase ControlJournal of Biological Chemistry, 2001
- Class B Scavenger Receptors, Caveolae and Cholesterol HomeostasisTrends in Cardiovascular Medicine, 1999
- Bezafibrate and clofibric acid are novel inhibitors of phosphatidylcholine synthesis via the methylation of phosphatidylethanolamineBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteinsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kB activityCarcinogenesis: Integrative Cancer Research, 1996
- Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.Journal of Clinical Investigation, 1996
- Kinetics of biliary secretion of chylomicron remnant cholesterol (esters) in the ratEuropean Journal of Biochemistry, 1993
- BIOCHEMISTRY OF PEROXISOMESAnnual Review of Biochemistry, 1992
- RECOVERY AND HYPERSECRETION OF INSULIN AND REVERSAL OF INSULIN RESISTANCE AFTER WITHDRAWAL OF SHORT-TERM CYCLOSPORINE TREATMENTTransplantation, 1992